Navigation Links
Martek Announces Fourth Quarter and FY 2009 Financial Results
Date:12/16/2009

$27.4 million, or 8.0% of revenue, a slight increase, on a percentage of revenue basis, from research and development spending levels in fiscal 2008. Martek's research and development focuses on both broadening the market applications for the Company's life'sDHA(TM) as well as leveraging the Company's microbial technology to develop new product offerings. The Company continues to expect quarter-to-quarter fluctuations in research and development expenses mainly due to the timing of outside services, including third-party clinical trial services.

During the fourth quarter of fiscal 2009, selling, general and administrative expenses ("SG&A") were $12.6 million, a decrease from $13.4 million in last year's fourth quarter. For the full fiscal year 2009, SG&A expenses as a percentage of revenue were approximately 14.5%, compared to 15.4% in fiscal 2008. The Company closely managed its SG&A spending levels and for fiscal 2009, SG&A was lower than in fiscal 2008 on both a percentage of revenue and absolute dollar basis.

Financial Position

As of the end of the fourth quarter, Martek had $141.1 million in cash and cash equivalents, a minimal amount of debt and the entire balance of its long-term revolving credit facility ($135 million) available for future borrowing. For the fiscal year ended October 31, 2009, the Company generated $65.8 million of cash from operating activities. Martek's year-end inventory value of approximately $116 million is consistent with previously disclosed expectations and reflects a reduction of over 7% from amounts held at the end of the Company's third quarter.

Significant Recent Events

  • Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case -- In September 2009, the United States Court of Appeals for the Federal Circuit ruled in Martek's favor in appeal proceedings related to a patent infringement law
    '/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Martek Signs Sole-Source Supply Agreement with Fonterra
2. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
3. Martek Announces Addition to Its Board of Directors
4. Martek to Present at Two Upcoming Investor Conferences
5. Martek Announces Settlement of Patent Dispute with Capsugel France
6. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
7. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
8. Martek to Announce Third Quarter 2009 Results
9. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.
10. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
11. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... and inflammatory diseases, today,announced that the U.S. ... its,Investigational New Drug (IND) application for its ... ), ENMD-2076 is a novel, ...
... Cinpathogen, through its,partnership in the Fudan-Cinpathogen Clinical and ... consulting,services to Shanghai area hospitals. For the past ... the Center has diagnosed and characterized over 3000,cases ... area,hospitals and colleagues at Fudan University, the University ...
... N.C., Jan. 3 Chimerix, Inc., a,biotechnology company ... Frazer, M.B., Ch.B., FRCA, FFPM has joined the,company ... Chimerix, Dr. Frazer served as the Chief Medical,Officer ... Medical) where he was responsible for the design ...
Cached Biology Technology:EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 2EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... head impact injury are an interesting scientific question. Professor ... for Biomechanics and Mechanobiology of the Ministry of Education, ... and the School of Materials Science and Engineering, Wuhan ... After 3 years of innovative research, they are making ...
... to achieve goals set by the federal government for reducing ... need to eliminate an average of 64 excess calories per ... American Journal of Preventive Medicine . This reduction could ... both. Without this reduction, the authors predict that the average ...
... Ill. -- Researchers have determined that bacteria are present ... the common belief that normal urine is sterile. These ... Journal of Clinical Microbiology by researchers at ... "Doctors have been trained to believe that urine is ...
Cached Biology News:Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2How many calories does it take to reach childhood obesity prevention goals? 2How many calories does it take to reach childhood obesity prevention goals? 3Loyola study debunks common myth that urine is sterile 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: